The role of G‐CSF in preventing neutropenia and infections was investigated in non‐Hodgkin's lymphoma patients (with the WHO classification, most of the participating patients would be currently classified as DLBCL).25 Neutropenia occurred in 37% of the G‐CSF‐treated patients and 85% of the controls, which indicates that the relative risk for control patients was 2.31 (P = 0.00001). The gene discussed is CSF3; the disease is infection.